Third Harmonic Bio Inc.

NASDAQ THRD

Data sourced from

and

Download Data

Third Harmonic Bio Inc. Depreciation and Amortization for the Trailing 12 Months (TTM) ending March 31, 2024: USD 44.00 K

Third Harmonic Bio Inc. Depreciation and Amortization is USD 44.00 K for the Trailing 12 Months (TTM) ending March 31, 2024, a 101.73% change year over year. Depreciation and Amortization involve the systematic allocation of the cost of tangible and intangible assets over their useful lives.

Third Harmonic Bio Inc. Depreciation and Amortization for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -2.55 M.

NASDAQ: THRD

Third Harmonic Bio Inc.

CEO	Ms. Natalie C. Holles
IPO Date	Sept. 14, 2022
Location	United States
Headquarters	300 Technology Square, Cambridge, MA, United States, 02139
Employees	31
Sector	Healthcare
Industry	Biotechnology

Description

Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is also developing THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated skin, respiratory, and gastrointestinal conditions. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.

Key trends